Previous studies have shown that Bcl-2 and Bcl-xL proteins appear to be involved in chemoresistance in ovarian carcinoma [30]–[32], and that reduced Bax expression is associated with cisplatin resistance in ovarian carcinoma cell systems [33]. Here, BCL2L1 is linked to ovarian carcinoma.